Efficacy of statins in preventing progression of aortic stenosis

American Journal of Health-System Pharmacy

Volumn 62, Issue 9, 2005, Pages 979-981

  Quinn Jr , Daniel W ^c   Spinler, Sarah A ^a,b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANGIOCARDIOGRAPHY; AORTA STENOSIS; AORTA SURGERY; AORTA VALVE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ELECTRON BEAM TOMOGRAPHY; HEART CATHETERIZATION; HUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

EID: 17844373540     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.9.979     Document Type: Article

References (22)

1. Carabello B. Aortic stenosis. N Engl J Med. 2002; 346:677-82.
2. Bellamy M, Pellikka P, Klarich K et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002; 40:1723-30.
3. Faggiano P, Aurigemma G, Rusconi C et al. Progression of valvular aortic stenosis in adults: literature review and clinical implications. Am Heart J. 1996; 132:408-17.
4. Pearlman A. Medical treatment of aortic stenosis: promising, or wishful thinking? J Am Coll Cardiol. 2002; 40:1731-4.
5. Carabello B, Crawford M. Aortic stenosis. In: Crawford M, ed. Current diagnosis and treatment in cardiology. 2nd ed. New York: McGraw-Hill; 2003:108-20.
6. Bonow RO, Carabello B, de Leon AC Jr et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation. 1998; 98:1949-84.
7. Morgan-Hughes GJ, Roobottom CA, Marshall AJ. Aortic valve imaging with computed tomography: a review. J Heart Valve Dis. 2002; 11:604-11.
8. Cowell SJ, Newby DE, Burton J et al. Aortic valve calcification on computed tomography predicts the severity of aortic stenosis. Clin Radiol. 2003; 58:712-6.
9. Callister T, Raggi P, Cooil B et al. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998; 339:1972-8.
10. Lester S, Heilbron B, Gin K et al. The natural history and rate of progression of aortic stenosis. Chest. 1998; 113:109-14.
11. Otto CM. Aortic stenosis and hyperlipidemia: establishing a cause-effect relationship. Am Heart J. 2004; 147:761-3.
12. Chan KL. Aortic stenosis: a preventable disease? J Am Coll Cardiol. 2003; 42:593-9.
13. Drolet MC, Arsenault M, Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol. 2003; 41:1211-7.
14. O'Brien K, Reichenbach D, Marcovina S et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol. 1996; 16:523-32.
15. Braunwald E. Valvular heart disease. In: Braunwald E, Fauci A, Isselbacher K et al., eds. Harrison's principles of internal medicine. New York: McGraw-Hill; 2001:1643-713.
16. Yilmaz MB, Guray U, Yesim G et al. Lipid profile of patients with aortic stenosis might be predictive of rate of progression. Am Heart J. 2004; 147:915-8.
17. Antonini-Canterin F, Zuppiroli A, Popescu BA et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol. 2003; 92:1479-82.
18. Pate G, Tahir MN, Murphy RT et al. Anti-inflammatory effects of statins in patients with aortic stenosis. J Cardiovasc Pharmacol Ther. 2003; 8:201-6.
19. Shavelle D, Takasu J, Budoff M et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002; 359:1125-6. Letter.
20. Novaro G, Tiong I, Pearce G et al. Effect of hydroxymethylglutaryl coenzyme-A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001; 104:2205-9.
21. Rosenhek R, Rader F, Loho N et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004; 110:1291-5.
22. Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation. 2004; 110:1180-2.